Acute myeloid leukemia (AML) is an uncommon but potentially catastrophic diagnosis with
historically high mortality rates. The standard of care treatment remained unchanged for …

Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML)
is occurring rapidly. Since 2017, nine agents have been approved for various indications in …

The treatment landscape of acute myeloid leukemia (AML) is evolving, with promising
therapies entering clinical translation, yet patient responses remain heterogeneous, and …

Age-related change in human haematopoiesis causes reduced regenerative capacity,
cytopenias, immune dysfunction and increased risk of blood cancer,–, but the reason for …

Acquired mutations are pervasive across normal tissues. However, understanding of the
processes that drive transformation of certain clones to cancer is limited. Here we study this …

Mutations in the genes encoding the cytoplasmic and mitochondrial forms of isocitrate
dehydrogenase (IDH1 and IDH2, respectively; collectively referred to as IDH) are frequently …

Therapeutic resistance continues to be an indominable foe in our ambition for curative
cancer treatment. Recent insights into the molecular determinants of acquired treatment …

Fat mass and obesity-associated protein (FTO), an RNA N 6-methyladenosine (m 6 A)
demethylase, plays oncogenic roles in various cancers, presenting an opportunity for the …

With rapid advances in sequencing technologies, tremendous progress has been made in
understanding the molecular pathogenesis of acute myeloid leukaemia (AML), thus …

The abnormal regulation of alternative splicing is usually accompanied by the occurrence
and development of tumors, which would produce multiple different isoforms and diversify …